Co-relation of hepatitis C RNA load with antiviral therapy and risk factors among hepatitis C seropositive patients

Suchita Netam, Kshyudratika Priyadarsini, Nikita Sherwani, Suresh Chandravanshi, Neha Singh, Aparna Sahu
{"title":"Co-relation of hepatitis C RNA load with antiviral therapy and risk factors among hepatitis C seropositive patients","authors":"Suchita Netam, Kshyudratika Priyadarsini, Nikita Sherwani, Suresh Chandravanshi, Neha Singh, Aparna Sahu","doi":"10.18231/j.ijmr.2024.014","DOIUrl":null,"url":null,"abstract":"Hepatitis C virus is a bloodborne virus and the major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Viral load is the prognostic marker of the disease progression. The aim of this study is to determine the correlation of hepatitis C RNA load with antiviral therapy and its risk factors among the HCV seropositive patients. This study will be helpful in early assessment of the disease progression and its complications.The blood samples were collected over a period of one year from April 2022-March 2023. The serum was subjected to ELISA for Anti HCV Ab. Viral load quantification was done by MylabPathoDetect HCV Quantitative PCR Kit in HCV seropositive patients.About 18,882 patients were tested for HCV infection over a period of one year. 75 patients were positive for HCV infection. Prevalence of HCV was 0.39. The mean viral load was reduced from 3.08×10 IU/ml to 1.98×10 IU/ml and Sustained Viral Response (SVR12) was achieved in 63(84%) patients after effective treatment with direct acting antiviral agents. High risk sexual behavior was the most common risk factor observed in seropositive patients.The current study determines the reduction in mean viral load and achieving sustained viral response after the effective antiviral therapy at the earliest, which is helpful in prevention of disease progression and its complications.","PeriodicalId":13428,"journal":{"name":"Indian Journal of Microbiology Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Microbiology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijmr.2024.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis C virus is a bloodborne virus and the major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Viral load is the prognostic marker of the disease progression. The aim of this study is to determine the correlation of hepatitis C RNA load with antiviral therapy and its risk factors among the HCV seropositive patients. This study will be helpful in early assessment of the disease progression and its complications.The blood samples were collected over a period of one year from April 2022-March 2023. The serum was subjected to ELISA for Anti HCV Ab. Viral load quantification was done by MylabPathoDetect HCV Quantitative PCR Kit in HCV seropositive patients.About 18,882 patients were tested for HCV infection over a period of one year. 75 patients were positive for HCV infection. Prevalence of HCV was 0.39. The mean viral load was reduced from 3.08×10 IU/ml to 1.98×10 IU/ml and Sustained Viral Response (SVR12) was achieved in 63(84%) patients after effective treatment with direct acting antiviral agents. High risk sexual behavior was the most common risk factor observed in seropositive patients.The current study determines the reduction in mean viral load and achieving sustained viral response after the effective antiviral therapy at the earliest, which is helpful in prevention of disease progression and its complications.
丙型肝炎血清反应阳性患者的丙型肝炎 RNA 量与抗病毒治疗和风险因素的相关性
丙型肝炎病毒是一种血源性病毒,是慢性肝炎、肝硬化和肝细胞癌的主要病因。病毒载量是疾病进展的预后标志。本研究旨在确定丙型肝炎 RNA 量与抗病毒治疗的相关性,以及丙型肝炎病毒血清反应阳性患者的风险因素。这项研究将有助于对疾病进展及其并发症进行早期评估。血样采集时间为 2022 年 4 月至 2023 年 3 月,为期一年。血清经 ELISA 检测抗 HCV Ab。通过 MylabPathoDetect HCV 定量 PCR 试剂盒对 HCV 血清阳性患者进行病毒载量定量检测。75 名患者的 HCV 感染呈阳性。HCV 感染率为 0.39。经过直接作用抗病毒药物的有效治疗,63 名(84%)患者的平均病毒载量从 3.08×10 IU/ml 降至 1.98×10 IU/ml,并获得了持续病毒应答 (SVR12)。高危性行为是在血清反应阳性患者中观察到的最常见风险因素。目前的研究确定了平均病毒载量的降低,以及在尽早接受有效的抗病毒治疗后获得的持续病毒应答,这有助于预防疾病进展及其并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信